ConserV Bioscience pan-coronavirus project has been awarded UK Aid funding by the UK Vaccine Network, delivered by Innovate UK

ConserV Bioscience Limited (“ConserV”), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, has been awarded UK Aid funding to advance development of its pan-coronavirus vaccine candidate, UNICOR-v. The project was selected by the UK Vaccine Network (UKVN) for the award under the competition “Vaccines for epidemic diseases: Readiness for clinical development and regulatory submission.” This is one of twenty-two projects funded by the Department of Health and Social Care as part of the UKVN, a UK Aid programme to develop vaccines for diseases with epidemic potential in low and middle-income countries (LMICs). ConserV specialises in identifying broadly protective antigens for highly mutable viruses. The grant will fund preclinical development of an intra-dermal formulation of UNICOR-v, which consists of twelve antigens from conserved regions of internal viral proteins that include clusters of reactive T-cell epitopes for multiple human leukocyte antigens (HLAs)